Bristol-myers Squibb Compnay

Universitéde Montreal

Eldon Scott Priestley

Xiaojun Zhang

Jeremy M Richter

Edward H Ruediger

R Michael Lawrence

Shoshana L Posy

Michael Matthew Miller

Jacques Banville

Marc Gagnon

Oz Scott Halpern

Pancras C Wong

Brad D Maxwell

Julia Guy

Samuel Kaye Reznik

Daniel H Deon

Nicholas Ronald Wurtz

Rajeev S Bhide

Peter W Glunz

Manoranjan Panda

Prashantha Gunaga

Roger Remillard

Vladimir Ladziata

Rajesh Onkardas Bora

Laurence Dube

Daniel L Cheney

Navnath Dnyanoba Yadav

Wen Jiang

Wu Yang

James Gillard

Rejean Ruel

Alexandra A Nirschl

Sasmita Tripathy

Yan Zou

Brandon Lee Parkhurst

Laurence Dubé

Roger Rémillard

James A Johnson

Alain Martel

Thomas W Hudyma

Carl P Decicco

Xiaofan Zheng

Anne Marinier

Qinghong Fu

Luciano Mueller

Michael R Lawrence

J Alex Bates

François Tremblay

Francois Tremblay

Laurence DubÉ

The present invention provides thiazole compounds of Formula I wherein W, Y, R, R, R, R, R, R, X, X, Xand Xare as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation

Disclosed are compounds of Formula (I) to (VIII): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein Ris a bicyclic heteroaryl group substituted with zero to 3 R; and R, R, R, R, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

Bicyclic heteroaryl substituted compounds

The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or β-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.

Biarylmethyl heterocycles

Disclosed are compounds of Formula (I) to (VIII): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein Ris a tricyclic heteroaryl group substituted with Rand zero to 2 R; and R, R, R, R, R, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors

Disclosed are compounds of Formula (I) or a salt thereof,wherein Ris: each W is independently NRor O; Z is a bond or CHR; and R, R, R, R, R, L, B, V, Y, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

Substituted nitrogen containing compounds

The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or &#x3b2;-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.

Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation

Disclosed are compounds of Formulas (I), (II), (III), (IV), (V), (VI), (VII), or (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII) or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein Ris a monocyclic heteroaryl group substituted with zero to 3 R; and R, R, R, R, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder. 

Monocyclic heteroaryl substituted compounds

Disclosed are compounds of Formula (I) to (IV): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder. 

Disclosed are compounds of Formula (I) or a salt thereof, wherein Ris (II) or (III); each W is independently NRor O; Z is a bond or CHR; and R, R, R, R, L, L, R, R, R, and n are define herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases. 

Substituted bicycle heterocyclic derivatives useful as ROMK channel inhibitors

The present invention provides thiazole compounds of Formula I wherein W, Y, R, R, R, R, R, R, X, X, Xand Xare as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders. 

The present invention provides imidazothiadiazole compounds of Formula (I); Wherein W, Y, R, R, R, R, R, X, X, Xand Xare as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders. 

Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation

Growing community of inventors

Yardley, PA, United States of America

Eldon Scott Priestley